These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29620287)

  • 21. Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma.
    Zhong J; Cao RX; Zu XY; Hong T; Yang J; Liu L; Xiao XH; Ding WJ; Zhao Q; Liu JH; Wen GB
    FEBS J; 2012 Jan; 279(2):316-35. PubMed ID: 22093364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
    Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
    PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
    Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
    Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
    Wang ZY; Yin L
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
    Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
    J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase in hyaluronic acid degradation decreases the expression of estrogen receptor alpha in MCF7 breast cancer cell line.
    Hanoux V; Eguida J; Fleurot E; Levallet J; Bonnamy PJ
    Mol Cell Endocrinol; 2018 Nov; 476():185-197. PubMed ID: 29753772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
    Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
    Molecules; 2022 May; 27(11):. PubMed ID: 35684480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
    Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
    Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell.
    Zhang F; Feng F; Yang P; Li Z; You J; Xie W; Gao X; Yang J
    Int J Biochem Cell Biol; 2012 Feb; 44(2):320-6. PubMed ID: 22094188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
    Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
    Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.